Table 3. Efficacy Parameter.

Efficacy by RECIST, per cent by change in target lesions baseline to V15, by tumor marker levels, per cent by baseline to V15, TTP and OS in weeks

Patient Number	RECIST	% change target lesion	New non-target lesion	Tumor Marker Change in % Baseline to V15		TTP (months)	OS (months)
1	SD	+ 18.7	None	CEA	+11,7	3.33	4.37
				CA19-9	+88,5
2	SD	+ 11.3	None	CEA§	+33,8	1.57	2.27
				CA19-9§	+49,1
3	SD	+ 8.7	None	CEA	+85,0	2.37	11.47*
				CA-19-9	+1401,3
4	SD	+ 11.1	None	CEA	-11,1	4.7	11.03*
				CA-19-9	+0,4
5	PD	+ 31.7	None	CEA	+52,3	1.27	3.57
				CA-19-9	-23,1
6	PD	+ 21.5	+1 lung	CEA§	+500,7	0.53	0.97
				CA-19-9§	+1847,8

* alive at last visit

^§ measured at V14